Highlight of this research
Background
Method
Study population
Definitions
Study end points
Statistical analysis
Result
Lesion and procedural characteristics
Comparison among the low-risk, intermediate-risk, and high-risk groups
Variable | CHA2DS2-VASc Score | p-value | ||
---|---|---|---|---|
low risk (1 point, n = 64) | intermediate risk (2–3 points, n = 135) | high risk (≥4 points, n = 40) | ||
Age (years), mean (SD) | 53.0 ± 7.5 | 59.1 ± 6.4 | 67.9 ± 7.9 |
P<0.001
|
Gender (female), n(%) | 0 | 63 (47.4) | 19 (47.5) |
P<0.001
|
Body mass index (Kg/m2) | 25.3 ± 1.8 | 24.4 ± 2.9 | 24.3 ± 2.6 |
0.04
|
Diabetes Mellitus, n(%) | 0 | 20 (14.8) | 20 (50.0) |
P<0.001
|
Hypertension, n(%) | 0 | 34 (25.2) | 27 (67.5) |
P<0.001
|
Stroke history, n(%) | 0 | 2 (1.5) | 6 (15.0) |
P<0.001
|
Current smoker, n(%) | 17 (26.6) | 45 (33.3) | 8 (20.0) | 0.23 |
Previous MI, n(%) | 19 (29.2) | 46 (34.1) | 11 (25.5) | 0.67 |
Systolic blood pressure (mmHg) | 119.1 ± 13.7 | 121.8 ± 12.1 | 124.6 ± 14.2 | 0.28 |
Diastolic blood pressure (mmHg) | 74.7 ± 10.0 | 74.2 ± 9.3 | 72.4 ± 5.8 |
0.015
|
Pulse pressure (mmHg) | 44.4 ± 10.2 | 47.6 ± 9.7 | 52.2 ± 12.2 |
0.001
|
LVEF | 0.51 ± 0.04 | 0.45 ± 0.06 | 0.43 ± 0.04 |
P<0.01
|
NYHA 2–3 on admision | 0 | 20 (14.8) | 17 (42.5) |
P<0.01
|
Total Cholesterol (mmol/L) | 4.2 ± 1.0 | 4.3 ± 1.1 | 4.3 ± 0.9 | 0.70 |
LDL-C (mmol/L) | 2.6 ± 0.6 | 2.5 ± 0.6 | 2.7 ± 0.6 | 0.23 |
HDL-C (mmol/L) | 1.1 ± 0.3 | 1.1 ± 0.3 | 1.2 ± 0.4 | 0.25 |
Triglyceride (mmol/L) | 1.6 ± 1.2 | 1.5 ± 1.3 | 1.3 ± 0.8 | 0.59 |
Fasting Glucose (mmol/L) | 5.3 ± 0.5 | 5.5 ± 0.8 | 5.8 ± 1.0 |
0.027
|
eGFR baseline (ml/min/1.73m2) | 102.0 ± 13.8 | 92.8 ± 17.0 | 89.5 ± 17.6 |
P<0.001
|
eGFR after PCI (ml/min/1.73m2) | 98.4 ± 14.2 | 87.4 ± 19.5 | 76.2 ± 21.3 |
P<0.001
|
First Day Creatinine (μmol/l) | 68.8 ± 19.2 | 69.5 ± 16.9 | 65.0 ± 17.6 | 0.37 |
Uric acid (μmol/l) | 330.3 ± 69.9 | 330.8 ± 69.8 | 336.1 ± 75.6 | 0.90 |
Total amount of conrrast (ml) | 181.8 ± 63.5 | 241.8 ± 104.0 | 320.3 ± 92.5 |
P<0.001
|
Total time of procedure (min) | 74.4 ± 45.6 | 96.1 ± 47.7 | 129.7 ± 51.6 |
P<0.001
|
The retrograde approach, n(%) | 14 (21.5) | 29 (21.5) | 14 (35.0) | 0.19 |
Transradial + transfemoral approach, n(%) | 21 (32.8) | 42 (31.1) | 17 (42.5) | 0.40 |
IABP, n(%) | 4 (6.3) | 6 (4.4) | 7 (17.5) |
0.02
|
IVUS, n(%) | 4 (6.3) | 9 (6.7) | 5 (12.5) | 0.42 |
Stent number | 1.9 ± 0.3 | 2.3 ± 0.6 | 2.6 ± 1.1 |
P<0.001
|
Glycoprotein IIb/IIIa receptor inhibitor, n(%) | 12 (18.8) | 24 (17.8) | 13 (32.5) | 0.12 |
CIN | 4 (6.3) | 20 (14.8) | 15 (37.5) |
P<0.001
|
Comparison between the CIN and non-CIN group
Variable | contrast-induced nephropathy | P-value | |
---|---|---|---|
Yes (n = 39) | NO (n = 200) | ||
Age (years), mean (SD) | 58.4 ± 8.4 | 64.5 ± 14.7 |
P<0.001
|
Gender (female), n(%) | 17 (43.6) | 65 (32.5) | 0.13 |
Body mass index (Kg/m2) | 24.6 ± 2.7 | 24.7 ± 2.4 | 0.85 |
Diabetes Mellitus, n(%) | 11 (28.2) | 29 (14.5) |
0.04
|
Hypertension, n(%) | 21 (53.8) | 40 (20.0) |
P<0.001
|
Stroke history, n(%) | 5 (12.8) | 3 (1.5) |
0.004
|
Current smoker, n(%) | 7 (17.9) | 63 (31.5) | 0.06 |
Previous MI, n(%) | 15 (38.5) | 50 (25.0) | 0.11 |
Systolic blood pressure (mmHg) | 120.6 ± 12.6 | 126.5 ± 13.8 |
0.009
|
Diastolic blood pressure (mmHg) | 74.5 ± 9.2 | 72.1 ± 8.1 |
P<0.001
|
Pulse pressure (mmHg) | 54.4 ± 12.1 | 46.1 ± 9.7 |
P<0.001
|
LVEF | 0.47 ± 0.07 | 0.44 ± 0.06 |
0.02
|
NYHA 2–3 on admision | 7 (17.9) | 30 (15.0) | 0.40 |
Total Cholesterol (mg/dl) | 4.4 ± 0.7 | 4.3 ± 1.1 | 0.33 |
LDL-C (mmol/L) | 2.8 ± 0.5 | 2.5 ± 0.6 |
0.007
|
HDL-C (mmol/L) | 1.0 ± 0.2 | 1.1 ± 0.3 | 0.09 |
Triglyceride (mmol/L) | 1.4 ± 0.6 | 1.5 ± 1.3 | 0.35 |
Fasting Glucose (mmol/L) | 5.4 ± 0.7 | 5.8 ± 1.3 |
0.004
|
Baseline eGFR (ml/min/1.73m2) | 94.6 ± 17.6 | 92.7 ± 20.3 | 0.53 |
Baseline Creatinine (μmol/l) | 69.2 ± 18.0 | 65.3 ± 15.6 | 0.21 |
Uric acid (μmol/l) | 355.4 ± 72.4 | 326.9 ± 69.4 |
0.02
|
Total amount of conrrast (ml) | 299.2 ± 105.2 | 227.1 ± 98.3 |
P<0.001
|
The retrograde approach, n(%) | 6 (15.4) | 51 (25.5) | 0.12 |
Transradial + transfemoral approach, n(%) | 12 (30.8) | 68 (34.0) | 0.85 |
Procedural duration (min) | 91.0 ± 50.0 | 120.9 ± 48.4 |
P<0.001
|
IABP, n(%) | 3 (7.7) | 14 (7.0) | 0.75 |
IVUS, n(%) | 4 (10.3) | 14 (7.0) | 0.51 |
Stent number | 2.2 ± 0.9 | 2.2 ± 0.6 | 0.96 |
Glycoprotein IIb/IIIa receptor inhibitor, n(%) | 18 (46.2) | 31 (15.5) |
P<0.001
|
CHA2DS2-VASc Score | 3.1 ± 1.2 | 2.1 ± 1.1 |
P<0.001
|
Variable | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
OR | P-value | OR(95%) | P-value | |
Pulse pressure (mmHg) | 1.126 |
0.042
| 1.042 (1.012–1.197) |
0.014
|
LDL-C (mg/dl) | 1.014 |
<0.001
| 1.174 (1.023–1.347) | 0.492 |
Uric acid (μmol/l) | 1.008 |
0.029
| 1.002 (1.000–1.013) | 0.193 |
Baseline eGFR (ml/min/1.73m2) | 0.549 |
<0.001
| 0.662 (0.521–0.789) |
0.012
|
Total amount of conrrast (ml) | 1.971 |
<0.001
| 1.772 (1.342–2.128) |
0.039
|
CHA2DS2-VASC risk score ≥ 3 | 7.743 |
<0.001
| 6.679 (3.169–15.531) |
<0.001
|